SuperworthIonis Pharmaceuticals IONS
- Market cap
- $7.1B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 8.2×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $874.1M
- −7% on a year ago
- Net margin
- −64.7%
- Free cash flow yield
- −7.9%
Ionis Pharmaceuticals trades at 8.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $874.1M over the last twelve months, down 7% on a year earlier with a −65% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $144.2M−10% | $324.5M+114% | $119.5M−8% | $225.3M+20% | $133.8M−7% | $226.6M−30% | $131.6M+10% | $452M+101% | $156.7M+17% | $203.3M−10% | $246.1M+87% | $267.9M−41% | |
| Cost of revenue | $2.2M+45% | $3.1M−17% | $2.2M+60% | $4.2M+64% | $1.1M−51% | $3.8M+25% | $1.5M−32% | $4.2M−0% | $2.3M+118% | $8M+108% | $3M+104% | $2.7M−34% |
| Gross profit | $142M−10% | $321.4M+117% | $117.3M−9% | $221.1M+19% | $132.7M−7% | $222.7M−31% | $130.1M+11% | $447.9M+103% | $154.4M+16% | $195.4M−12% | $243.1M+87% | $265.2M−41% |
| R&D | $215.3M+18% | $256.6M−17% | $214.2M+8% | $222.1M−3% | $219.8M+2% | $245.5M−4% | $200.8M−6% | $217.5M−2% | $217.8M−1% | $279.6M+14% | $210.2M+5% | $217.1M−0% |
| SG&A | $70M+103% | $71M+48% | $52.6M+16% | $65.1M+41% | $61.6M−12% | $88.1M+24% | $76.3M+45% | $90.6M+39% | $96.8M+57% | $130.2M+48% | $150.4M+97% | $150.4M+66% |
| −$143.3M+142% | −$6.1M−97% | −$149.5M+31% | −$66.1M−27% | −$148.7M+4% | −$110.8M+1710% | −$146.9M−2% | $139.8M | −$160.2M+8% | −$214.5M+94% | −$117.4M−20% | −$102.3M | |
| Interest expense | $4.2M+97% | $4.6M+163% | $4.2M+158% | $4.5M+96% | $4.2M−1% | $4.2M−8% | $4.1M−1% | $4.1M−8% | $4.2M+1% | $4.8M+15% | $5.2M+26% | $4.6M+12% |
| Pre-tax income | −$140.8M+202% | −$2.8M−94% | −$142.7M+26% | −$66.2M−15% | −$144.1M+2% | −$107M+3768% | −$146.8M+3% | $123.5M | −$128.4M−11% | −$227.9M+113% | −$92.3M−37% | −$113.4M |
| $6.6M+2233% | $6.5M−20% | $75K−99% | $64K−99% | −$3.6M | −$2.7M | $116K+55% | −$20K | $213K | $1.5M | $218K+88% | $1.3M | |
| Net income | −$147.4M+214% | −$9.3M−82% | −$142.8M+15% | −$66.3M−22% | −$140.5M−5% | −$104.3M+1027% | −$146.9M+3% | $123.6M | −$128.6M−9% | −$229.4M+120% | −$92.5M−37% | −$114.6M |
| −$1.03+212% | −$0.06−84% | −$0.98+13% | −$0.45−25% | −$0.95−8% | −$0.66+1000% | −$0.93−5% | $0.70 | −$0.80−16% | −$1.41+114% | −$0.56−40% | −$0.69 | |
| 143.3M+1% | 143.6M+1% | 145.5M+2% | 146M+2% | 148.6M+4% | 157.9M+10% | 158.7M+9% | 182.3M+25% | 159.8M+8% | 162.4M+3% | 164.9M+4% | 165.4M−9% |
Gross profit: 33 periods, Q1 FY18 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 15 periods, Q3 FY11 to Q1 FY15: not printed by the filing, worked out from its own lines.
EPS, diluted: 12 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 11 periods, Q4 FY09 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY14 to Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Ionis Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IONSIonis Pharmaceuticals | $7.1B | n/m | 51.9× | 8.2× | −7% | −64.7% | |
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| TGTXTG Therapeutics | $8.3B | 19.8× | 19.4× | 10.4× | +76% | 55.2% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| PTGXProtagonist Therapeutics | $9B | 134× | 58.3× | 31.8× | +35% | 29.4% | |
| CORTCorcept Therapeutics | $9.3B | 204× | 28.3× | 11.2× | +16% | 6.6% | |
| BMRNBiomarin Pharmaceutical | $10.8B | 151× | 70.6× | 3.2× | +11% | 2.1% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| Peer median | $6.9B | 97.0× | 44.6× | 7.8× | +25% | 8.1% |
Investors who own it
Investors we follow who held Ionis Pharmaceuticals at the end of Jun 30, 2026, from their 13F filings.
- Cathie WoodARK Investment Management0.2% of portfolioadded
- Ron BaronBaron Capital0.0% of portfoliotrimmed
More on Ionis Pharmaceuticals
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .